Rapid Hybridoma

Hybridoma antibody technology produces monoclonal antibodies but faces challenges like instability and the need for liquid nitrogen preservation. Hybridoma sequencing enables recombinant expression, ensuring stability and preventing biological contamination.

AtaGenix offers high-accuracy hybridoma sequencing and recombinant antibody expression, achieving 200-500 mg/L yields in 2 weeks with the proprietary pATX3.0 vector.

Flexible Sample Options

Accepts both cultured cells and frozen cell lines for seamless processing
Rapid Turnaround

Delivers results within just 2 weeks, ensuring efficiency
Comprehensive Analysis

Offers variable region and full-length sequencing, with detailed reports including CDR region analysis

Rapid Hybridoma Technology Roadmap

At AtaGenix, we pride ourselves on over 10 years of expertise in delivering custom hybridoma monoclonal antibody services. Our process is designed to meet the highest standards of quality and efficiency, ensuring your research and therapeutic projects are supported by the best monoclonal antibodies available.

Rapid Hybridoma Case Studies

Hybridoma Sequencing

Hybridoma sequencing enables the precise identification of heavy and light chain variable regions of monoclonal antibodies. The data includes high-quality PCR amplification, colony validation gels, and sequencing results, ensuring accuracy in gene identification and antibody production.

By Method

By Application

Rapid Hybridoma

Rapid Hybridoma Technology Roadmap

Rapid Hybridoma Case Studies

Hybridoma Sequencing

More Featured Antibody Services

Featured Services

Ask us

About us

Core Technologies

Resource Center